Arrowstreet Capital
SPRO icon

Arrowstreet Capital’s Spero Therapeutics SPRO Stock Holding History

Arrowstreet Capital’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$736K Buy
+332,970
New +$871K ﹤0.01% 1697
2025
Q4 		– Sell
-150,516
Closed -$283K – 2015
2025
Q3 		$283K Buy
+150,516
New +$331K ﹤0.01% 1767
2020
Q4 		– Sell
-34,225
Closed -$382K – 2517
2020
Q3 		$382K Buy
34,225
+6,483
+23% +$76.7K ﹤0.01% 2087
2020
Q2 		$375K Buy
+27,742
New +$311K ﹤0.01% 2044

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Arrowstreet Capital's SPRO Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 332,970 shares worth $736K. The stake represents ﹤0.01% of the portfolio and ranks #1697 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in SPRO as recently as Q3 2025.

Arrowstreet Capital first reported a position in SPRO in Q2 2020 and has held it in 4 quarters since. 34 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Arrowstreet Capital held 332,970 shares of Spero Therapeutics worth $736K as of Q2 2026.
  • Spero Therapeutics was a new Arrowstreet Capital position in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1697 holding.
  • Arrowstreet Capital first reported a position in Spero Therapeutics in Q2 2020 and has held it in 4 quarters since.
  • 34 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.